The phase III IMpower010 trial reinforced the significant disease-free survival benefit offered by Tecentriq (atezolizumab) for people with stage II-IIIA non-small cell lung cancer whose tumors express PD-L1≥1%.
MIT researchers found that benzo(a)pyrene plays a small part—about 11%—in the global risk of developing polycyclic aromatic hydrocarbons (PAHs)-associated cancer.
A study published in the Journal of the National Comprehensive Cancer Network found that more than 80% of therapies tested in phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival.
Updated results from CStone Pharmaceuticals’ phase III GEMSTONE-302 study indicate the effectiveness of the antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with stage IV non-small cell lung cancer.
Cabometyx (cabozantinib) offers efficacy benefits in combination with Bristol Myers Squibb’s Opdivo (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma, regardless of prior nephrectomy status, according to data from a post-hoc exploratory analysis of the phase III CheckMate -9ER pivotal trial.
The Leukemia & Lymphoma Society published a study showing that more than one in two patients with B-cell blood cancers produced antibodies to a third dose of COVID-19 vaccine, despite having no detectable antibodies after the first two doses.
Researchers at MD Anderson Cancer Center demonstrated that stereotactic ablative radiotherapy was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer and generated minimal side effects.
Keck School of Medicine of USC researchers found that children born with a genetic predisposition to produce more lymphocytes, particularly in relation to other types of white blood cells, are at a higher risk of developing acute lymphoblastic leukemia.
Cedars-Sinai Cancer and Tempus, an artificial intelligence and precision medicine company, are using big data and AI to design personalized cancer treatment options, creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each individual’s disease.
As adolescents return to school, public health experts caution parents to pay close attention to signs of tobacco use among teens.
